Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system (CNS) disorders and rare diseases. Headquartered in San Diego, California, the company's commercial portfolio includes FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Acadia primarily operates in the United States, targeting underserved patient populations with specialized neurological needs.

Financials

Earnings Transcripts

Leadership & board

Acquisitions

ACADIA does not have a share repurchase or buyback program. As a growth-stage commercial biopharmaceutical company, it reinvests cash flow into its commercial franchises (NUPLAZID and DAYBUE), its clinical pipeline, and business development, and its 10-K for the year ended December 31, 2025 discloses no stock repurchase authorization or activity. The company ended 2025 with roughly $820 million in cash and investments (rising to $956 million by the end of Q2 2026).

ACADIA sells NUPLAZID to a limited number of specialty pharmacies and specialty distributors and sells DAYBUE in the U.S. through a single wholesale distributor with specialty-pharmacy service. For the year ended December 31, 2025, four such customers, each based in the United States, accounted for approximately 79% of NUPLAZID product revenue and 44% of total product revenue, creating meaningful customer concentration. The company does not own manufacturing facilities and relies on an outsourced manufacturing strategy for both NUPLAZID and DAYBUE.

You're subscribed.

Thanks for signing up.